PDF

Download the Cell & Gene Therapy Manufacturing 2018

Download the Cell & Gene Therapy Manufacturing 2018

The Cell & Gene Therapy Manufacturing Forum is back for 2018!

Join us 13th - 15th November in London, UK to:

  • Develop a sustainable scalable manufacturing strategy, and discuss the individual requirements of Autologous and Allogenic therapies with expert guidance from Zelluna Immunotherapy
  • Identify common process bottlenecks and avoid manufacturing delays with insights from Pluristem Therapeutics that will ensure you do not end up left behind! 
  • Effectively invest in process development and manufacturing automation that will reduce your development timeline and generate a return on investment with an industry leading case study from Torque Therapeutics
  • Define your critical quality attributes that will underpin your product development, and discuss how to maximize delivery against these attributes with first hand tips and tricks from Autolus 
  • Ensure you are market ready through an expert analyse of the current global regulatory landscape for Cell and Gene Therapies with a focus on EU and US requirements with GSK and Rheincell Therapeutics sharing their perspectives

Making Medicines of The Future

Making Medicines of The Future

In this case study, Pharma IQ gains insight from Oxford BioMedica - a pioneer in the development of gene therapies for 20 years, focused mainly on lentiviral vectors. The ebook evaluates manufacturing trends, preparing for the commercial phases of gene therapies, combating extractables and leachables and scaling up. 
 
Cell & Gene Therapy Manufacturing Agenda

Cell & Gene Therapy Manufacturing Agenda

Download the Cell and Gene Therapy Manufacturing Agenda to find out more about the speakers, sessions and content.

Cell & Gene Manufacturing: Emerging Trends

Cell & Gene Manufacturing: Emerging Trends

Pharma IQ spoke to Dr Ryan Guest, Director of Cell Production from cell therapy manufacturer Cellular Therapeutics to explore the raft of emerging trends connected to cell and gene manufacturing.

Stem Cells: The Big Void of Toxicological Testing?

Stem Cells: The Big Void of Toxicological Testing?

In this interview Pharma IQ speak to James Sherley to find out what have been the major advancements in using stem cells for toxicology testing and the current challenges that need to be overcome in using stem cells for toxicology. In this interview you will also find out what are going to be the trends in using stem cells for toxicology over the coming 18 months.

INFOGRAPHIC: Global biomanufacturing activity & spend

INFOGRAPHIC: Global biomanufacturing activity & spend

Pharma IQ has created an easy-to-digest overview of biomanufacturing activity and spend around the world, whether they are already being implemented or have plans in the near future. You’ll be able to keep it as a handy reference, share it around your colleagues or even stick it on your wall!

Scale-Up and Manufacturing of Regenerative Medicine

Scale-Up and Manufacturing of Regenerative Medicine

When introducing a regenerative medicine cell based product to a commercial setting, there are a number of things to take into consideration to ensure a commercially viable and safe product for patient use. In this Q&A interview, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some great insights into the commercial manufacturing scale-up process of cell therapies.

Cell And Gene Manufacturing UK Heatmap

Cell And Gene Manufacturing UK Heatmap

In response to the region’s strengthening presence with the therapeutic method, Pharma IQ presents this Cell and Gene Manufacturing hotspot map.

Best Practice Guide Automation, Scale up & Scale Out

Best Practice Guide Automation, Scale up & Scale Out

One key point of focus for the market is not only the move towards scaling up - manufacturing bigger batches of product- but also scaling out - manufacturing more batches.

In response, to this Pharma IQ spoke to Elena Meurer of apceth GmbH & Co.KG to compile this best practise guide automation scale up –and scale out for cell and
gene therapies.

Cell and Gene Therapy Europe Heatmap

Cell and Gene Therapy Europe Heatmap

Over the last 12 months, the cell and gene therapy manufacturing sphere has matured vastly with more companies advancing to commercial products, especially with allogenic therapies. Now that the theory behind the therapy is catching up with the technology, the two can come together to progress towards producing commercial products. In this Cell and Gene Manufacturing hotspot map,  we have broadened our focus to scan the cell and gene manufacturing activity that is occurring across Europe regarding the road to commercialised therapies.
Producing Off-The-Shelf Cell and Gene Products

Producing Off-The-Shelf Cell and Gene Products

The rise of personalised medicines has led to the focus on small scale manufacture with a key challenge being that lots of the same element will run through a facility at once. Randomised trials with complex gene therapies- which target a small number of patients often in regards to orphan diseases can encounter various manufacturing hurdles. Also, evidence is needed to prove efficacy against historical controls with Phase II trials. This of course requires several years of data which is limited, incurring implications on cost and time to market. Ahead of the Cell and Gene Therapy Manufacturing conference Pharma IQ examines the various challenges that complicate the route to producing off the shelf cell and gene products.
Overcoming Manufacturing Challenges in the Race to Market

Overcoming Manufacturing Challenges in the Race to Market

Fast on its way to becoming a multibillion-dollar market, the global cell and gene therapy industry is booming. However, challenges mean that almost three decades after the first gene therapy trial, only three gene therapies have been approved in the EU and one in the United States. This article will look into the challenges around development and manufacturing that need to be addressed so that ambitious pharma and biotechs can continue to develop these innovative medicines. 


Past Presentation: Identify the Opportunities and Challenges in Advanced Therapy Manufacturing Process (ATMP)

Past Presentation: Identify the Opportunities and Challenges in Advanced Therapy Manufacturing Process (ATMP)

Magda Papadaki, Head of Manufacturing Innovation, The Association of the British Pharmaceutical Industry (ABPI) shares her presentation from last year's Cell & Gene Therapy Manufacturing Forum: 'Identify the Opportunities and Challenges in Advanced Therapy Manufacturing Process (ATMP)'.

In this presentation:

  • Determine what to consider when moving from research to commercial production
  • Understand what different set backs will become apparent when looking at cost efficiency of manufacturing 
  • Hear the recommended actions that need to be considered when in the positions of discovery and development of advanced therapies
Cell & Gene Therapy: European Heatmap

Cell & Gene Therapy: European Heatmap

The cell and gene therapy manufacturing sphere continues to mature rapidly, with a growing number of companies moving towards commercialising products. This infographic provides a high level overview of the latest developments in the European cell and gene therapy manufacturing space, looking at which therapies are moving into commercialisation in order to treat a wide range of conditions and diseases.

Cell & Gene Therapy: Industry Report

Cell & Gene Therapy: Industry Report

The cell and gene therapy manufacturing sphere continues to mature rapidly, with a growing number of companies moving towards commercialising products. This report includes a European Heatmap which provides a high level overview of the latest developments in the European cell and gene therapy manufacturing space, in addition to an detailed industry update which provides information about therapy development throughout Europe.